Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 4/20 | 0.64 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.64 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.64 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.64 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.43 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.43 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 2/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3690738 | 1.00 | HTR1A (0.64) | HTR1AADRA1DADRA1AADRA1BHRH3 | |
| SCHEMBL3685288 | 0.92 | HTR1A (0.60) | HTR1AADRA1DADRA1AADRA1BHRH3 | |
| SCHEMBL3680788 | 0.92 | HTR1A (0.60) | HTR1AADRA1DADRA1AADRA1BHRH3 | |
| SCHEMBL3678016 | 0.78 | HRH3 (0.49) | HTR1AHRH3LRRK2DRD2 | |
| SCHEMBL14761648 | 0.78 | HTR1A (1.00) | HTR1AADRA1DADRA1AADRA1BKDM4E | |
| SCHEMBL3685142 | 0.78 | HRH3 (0.49) | HTR1AHRH3LRRK2DRD2 | |
| SCHEMBL3680205 | 0.77 | HRH3 (0.46) | HRH3LRRK2DRD2 | |
| SCHEMBL8762637 | 0.76 | HRH4 (0.56) | HRH3KDM4ETRPV6HTR2C | |
| SCHEMBL8763960 | 0.76 | HRH4 (0.56) | HRH3KDM4ETRPV6HTR2C | |
| SCHEMBL8762631 | 0.76 | HRH4 (0.56) | HRH3KDM4ETRPV6HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1724267-B1 | PYRIMIDINE DERIVATIVE | ASKA PHARM CO LTD (JP) | 2013-11-06 | — | — | EP | disclosed |
| US-7799775-B2 | such as 3-amino-5,6-dimethyl-2-[3-(4-quinolin-2-ylpiperazin-1-yl)propylthio]-3H-thieno[2,3-d]pyrimidin-4-one, having serotonin receptor modulatory activity, used for treating irritable bowel syndrome | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2010-09-21 | — | — | US | disclosed |
| US-20070197551-A1 | Pyrimidine derivatives | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-23 | — | — | US | disclosed |
| EP-1724267-A1 | PYRIMIDINE DERIVATIVE | ASKA Pharmaceutical Co., Ltd. (JP) | 2006-11-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197551-A1 | Pyrimidine derivatives | HTR3B, HTR3A, HTR1A | HTR1A 3/4885ADRA1D 100/4885ADRA1A 103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.